Overview
ANVS market data
Price History
ANVS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.40 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.18 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.54 – $5.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $75.7M · P/B 5.44.
Company News
8-K filing — Annovis Bio, Inc. (ANVS)SEC EDGAR · Aug 14, 2026, 8:05 PM
Annovis Bio Q2 EPS $(0.40) Beats $(0.45) EstimateBenzinga · Aug 14, 2026, 12:10 PM
Annovis Bio Announces Full Enrollment Of Its Phase 3 Trial Of Buntanetap In Patients With Early Alzheimer’s Disease; The Trial Enrolled 850 Patients; Symptomatic Data Readout Expected In Q1 2027, and Disease-Modifying Data Readout Anticipated in Q1 2028Benzinga · Jul 7, 2026, 11:25 AM
Annovis Bio Announces It Has Regained NYSE Listing ComplianceBenzinga · May 26, 2026, 12:06 PM
Annovis Bio Prices Underwritten Public Offering Of 7,895,000 Shares And Warrants To Purchase Up To 7,105,500 Shares At $1.90 Per UnitBenzinga · May 20, 2026, 12:10 PM
Annovis Bio Announces Launch Of Proposed $250M Public Stock Offering Initially Filed February 12, 2024Benzinga · May 19, 2026, 8:20 PM
Annovis Bio Q1 EPS $(0.63) Misses $(0.40) EstimateBenzinga · May 15, 2026, 11:45 AM